KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Aquestive Therapeutics (AQST) Receivables - Other (2017 - 2026)

Aquestive Therapeutics has reported Receivables - Other over the past 9 years, most recently at $9.8 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 294.26% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, up 294.26%, while the annual FY2025 figure was $9.8 million, 294.26% up from the prior year.
  • Receivables - Other for Q4 2025 was $9.8 million at Aquestive Therapeutics, up from $2.3 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $9.8 million in Q4 2025 and troughed at $718000.0 in Q1 2025.
  • A 5-year average of $2.9 million and a median of $2.3 million in 2025 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: plummeted 64.35% in 2022 and later skyrocketed 294.26% in 2025.
  • Year by year, Receivables - Other stood at $6.0 million in 2021, then plummeted by 64.35% to $2.1 million in 2022, then skyrocketed by 36.28% to $2.9 million in 2023, then dropped by 15.16% to $2.5 million in 2024, then skyrocketed by 294.26% to $9.8 million in 2025.
  • Business Quant data shows Receivables - Other for AQST at $9.8 million in Q4 2025, $2.3 million in Q3 2025, and $2.2 million in Q2 2025.